SCHEMBL20135196

SCHEMBL20135196

Cc1ccc(C(=O)C2CCNCC2)nc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.58
CYP2D6 P10635 1/20 0.58
KMT2A Q03164 1/20 0.58
HRH3 Q9Y5N1 1/20 0.45
KDM1A O60341 1/20 0.40
POLB P06746 1/20 0.39
HTR3E A5X5Y0 1/20 0.38
HTR3B O95264 1/20 0.38
HTR3A P46098 1/20 0.38
HTR3D Q70Z44 1/20 0.38
HTR3C Q8WXA8 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
KDM5A P29375 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
KHK P50053 1/20 0.36
GABRP O00591 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17253040 0.89 TDP1 (0.42) MEN1CYP2D6KMT2APOLBTDP1
SCHEMBL17819837 0.80 KDM4A (0.47) MEN1KMT2AHRH3TDP1TSHR
SCHEMBL23407891 0.78 TMEM97 (0.41) MEN1CYP2D6KMT2AHRH3POLB
SCHEMBL18595333 0.77 TDP1 (0.46) MEN1KMT2APOLBTDP1MAPT
SCHEMBL1582773 0.75 KMT2A (0.96) MEN1CYP2D6KMT2AKDM1APOLB
SCHEMBL408199 0.74 CES2 (0.48) MEN1CYP2D6KMT2AHRH3HTR3E
SCHEMBL17820012 0.74 PDE10A (0.45) MEN1KMT2APOLBTDP1KDM5A
Hydrochloric Acid SCHEMBL2366330 0.73 KMT2A (1.00) MEN1CYP2D6KMT2AKDM1APOLB
Bromide SCHEMBL10968871 0.73 KMT2A (0.93) MEN1CYP2D6KMT2AKDM1APOLB
Hydrochloric Acid SCHEMBL439311 0.73 KMT2A (0.47) MEN1CYP2D6KMT2AHRH3HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MEN1 3735/4885CYP2D6 880/4885KMT2A 2568/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MEN1 2913/4885CYP2D6 691/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.